Monosymptomatic bedwetting

Area of Science:

• Pediatric Nephrology
• Sleep Medicine
• Endocrinology

Background:

• Monosymptomatic nocturnal enuresis (bedwetting) is a common condition with complex causes.
• Previous understanding suggested bladder dysfunction, but recent evidence indicates normal bladder capacity.
• A multifactorial pathogenesis involving arousal disturbances and disrupted circadian rhythms of hormones is implicated.

Purpose of the Study:

• To provide an updated overview of the pathogenesis and treatment of monosymptomatic nocturnal enuresis.
• To highlight the role of desmopressin acetate (DDAVP) in managing circadian rhythm disturbances of antidiuretic hormone.

Main Methods:

• Review of current literature on the pathogenesis of monosymptomatic nocturnal enuresis.
• Analysis of the efficacy of desmopressin acetate (DDAVP) in treating patients with altered arginine vasopressin (AVP) rhythms.
• Focus on understanding the role of circadian rhythm of diuresis modulating hormones.

Main Results:

• Bladder reservoir function is confirmed as normal in monosymptomatic nocturnal enuresis.
• Treatments targeting bladder instability have proven ineffective.
• Desmopressin acetate (DDAVP) effectively counteracts circadian rhythm changes in antidiuretic hormone, resolving symptoms in over two-thirds of patients.

Conclusions:

• Monosymptomatic nocturnal enuresis is primarily linked to arousal and hormonal circadian rhythm disturbances, not bladder issues.
• Monitoring arginine vasopressin (AVP) circadian rhythms and DDAVP treatment offer significant therapeutic benefits.
• This approach enhances understanding of enuresis pathogenesis and opens new research avenues.